A detailed history of Cubist Systematic Strategies, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 13,361 shares of URGN stock, worth $143,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,361
Previous 44,949 70.28%
Holding current value
$143,096
Previous $754,000 77.59%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.7 - $17.92 $401,167 - $566,056
-31,588 Reduced 70.28%
13,361 $169,000
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $493,523 - $744,940
38,799 Added 630.88%
44,949 $754,000
Q1 2024

May 15, 2024

BUY
$13.81 - $19.33 $82,970 - $116,134
6,008 Added 4230.99%
6,150 $92,000
Q4 2023

Feb 14, 2024

SELL
$10.87 - $15.93 $1.41 Million - $2.07 Million
-129,930 Reduced 99.89%
142 $2,000
Q3 2023

Nov 14, 2023

BUY
$8.84 - $22.64 $1.04 Million - $2.67 Million
117,718 Added 952.87%
130,072 $1.82 Million
Q2 2023

Aug 14, 2023

BUY
$8.75 - $14.29 $108,097 - $176,538
12,354 New
12,354 $127,000
Q1 2020

May 15, 2020

SELL
$13.68 - $34.6 $20,219 - $51,138
-1,478 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$21.11 - $34.86 $22,777 - $37,613
1,079 Added 270.43%
1,478 $49,000
Q3 2019

Nov 14, 2019

SELL
$23.83 - $36.44 $23 - $36
-1 Reduced 0.25%
399 $10,000
Q2 2019

Aug 14, 2019

SELL
$32.75 - $40.35 $354,944 - $437,313
-10,838 Reduced 96.44%
400 $14,000
Q1 2019

May 15, 2019

BUY
$35.47 - $54.55 $370,235 - $569,392
10,438 Added 1304.75%
11,238 $415,000
Q4 2018

Feb 14, 2019

BUY
$38.35 - $50.39 $26,960 - $35,424
703 Added 724.74%
800 $34,000
Q3 2018

Nov 14, 2018

SELL
$41.65 - $51.7 $274,765 - $341,064
-6,597 Reduced 98.55%
97 $5,000
Q2 2018

Aug 14, 2018

BUY
$48.35 - $65.33 $323,654 - $437,319
6,694 New
6,694 $333,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $244M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.